|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
ocn953456125 |
| 003 |
OCoLC |
| 005 |
20241006213017.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
160712s2016 enkaf ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d YDXCP
|d EBLCP
|d N$T
|d OCLCF
|d STBDS
|d OCLCQ
|d WRM
|d CUV
|d OCLCO
|d OCLCQ
|d OCLCA
|d OCLCQ
|d UKAHL
|d OCLCQ
|d OCLCO
|d OCL
|d OCLCQ
|d OCLCO
|d OCLCL
|d OCLCQ
|d REDDC
|d LOA
|d ELBRO
|
| 019 |
|
|
|a 945028029
|a 1148082560
|a 1441737046
|
| 020 |
|
|
|a 9780191045431
|q (electronic bk.)
|
| 020 |
|
|
|a 0191045438
|q (electronic bk.)
|
| 020 |
|
|
|a 9780191795909
|q (electronic bk.)
|
| 020 |
|
|
|a 0191795909
|q (electronic bk.)
|
| 020 |
|
|
|z 9780198729204
|
| 020 |
|
|
|z 0198729200
|
| 035 |
|
|
|a (OCoLC)953456125
|z (OCoLC)945028029
|z (OCoLC)1148082560
|z (OCoLC)1441737046
|
| 050 |
|
4 |
|a RC927.5.P6
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 049 |
|
|
|a HCDD
|
| 245 |
0 |
0 |
|a Polymyalgia rheumatica and giant cell arteritis /
|c edited by Bhaskar Dasgupta, Christian Dejaco.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a Oxford, United Kingdom :
|b Oxford University Press,
|c 2016.
|
| 300 |
|
|
|a 1 online resource :
|b illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Oxford rheumatology library
|
| 588 |
0 |
|
|a Print version record.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed September 12, 2016).
|
| 505 |
0 |
|
|a Cover; Polymyalgia Rheumatica and Giant Cell Arteritis; Copyright; Contents; Abbreviations; Contributors; Plates; Part 1 Epidemiology, pathogenesis, and clinical presentation; 1 Definition and epidemiology; 2 Aetiology and pathogenesis; 3 Clinical presentation and classification criteria for polymyalgia rheumatica; 4 Clinical manifestations of giant cell arteritis; Part 2 Diagnostic work-up; 5 Laboratory findings; 6 Ultrasound; 7 Temporal artery biopsy; 8 Positron emission tomography and magnetic resonance imaging; 9 Differential diagnosis; Part 3 Guidelines for treatment; 10 Glucocorticoids.
|
| 505 |
8 |
|
|a 11 Role of steroid-sparing agents12 Treatment of a relapse and approach to difficult-to-treat patients; 13 Management of sight loss and other disease- and treatment-related complications; Part 4 Outcomes, prognosis, socioeconomic implications, primary care, and patient perspectives; 14 Determination of disease activity and outcomes; 15 Prognosis and duration of therapy; 16 Primary care; 17 Socioeconomic implications; 18 Patient education; Index.
|
| 520 |
|
|
|a Part of the Oxford Rheumatology Library series, Polymyalgia Rheumatica and Giant Cell Arteritis provides quick and practically relevant information on several aspects of the diseases, particularly on diagnosis and management, with the ultimate aim of improving the patient's care.
|
| 520 |
|
|
|a Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related conditions occurring almost exclusively in older people. Polymyalgia rheumatica is considered to be the rheumatic disease that is subject to the widest variations of clinical practice, partially due to the considerable uncertainty related to diagnosis and outcomes. Giant cell arteritis, an inflammatory form of vasculitis, may present with a broad spectrum of clinical manifestations and can be complicated by acute ischemic events, the most serious of which is permanent blindness. Early recognition and adequate treatment of the condition is thus necessary to prevent patients' loss of independence and to maintain their quality of life. Part of the Oxford Rheumatology Library series, Polymyalgia Rheumatica and Giant Cell Arteritis provides quick and practically relevant information on several aspects of the diseases, particularly on diagnosis and management, with the ultimate aim of improving the patient's care. Chapters highlight current concepts of pathogenesis, recent advances of diagnostic and therapeutic approaches, and the ongoing research into the identification of new biomarkers and corticosteroid-sparing medications. Each chapter is complemented with key message boxes highlighting the most relevant information for clinical practice. This concise but comprehensive reference is particularly suited for rheumatologists, general practitioners, and other professionals caring for patients with PMR and GCA.
|
| 650 |
|
0 |
|a Polymyalgia rheumatica.
|
| 650 |
|
0 |
|a Giant cell arteritis.
|
| 650 |
|
0 |
|a Outcome assessment (Medical care)
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Outcome assessment (Medical care)
|2 fast
|
| 650 |
|
7 |
|a Giant cell arteritis
|2 fast
|
| 650 |
|
7 |
|a Polymyalgia rheumatica
|2 fast
|
| 700 |
1 |
|
|a Dāśagupta, Bhaskara,
|e editor.
|
| 700 |
1 |
|
|a Dejaco, Christian,
|e editor.
|
| 758 |
|
|
|i has work:
|a Polymyalgia rheumatica and giant cell arteritis (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCFGHWKTmRMdQK74DCPdWjC
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|t Polymyalgia rheumatica and giant cell arteritis.
|b First edition.
|d Oxford, United Kingdom : Oxford University Press, 2016
|z 0198729200
|z 9780198729204
|w (OCoLC)930009982
|
| 830 |
|
0 |
|a Oxford rheumatology library.
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/holycrosscollege-ebooks/detail.action?docID=4545382
|y Click for online access
|
| 903 |
|
|
|a EBC-AC
|
| 994 |
|
|
|a 92
|b HCD
|